(Bloomberg) -- German blood-plasma supplier Biotest AG said Sunday that talks about a possible private equity investment in the company are “at an early stage,” responding to a Bloomberg story that said that private equity firm Triton had approached its majority shareholder Creat Group Corp. about buying a stake.
“The consultations are at an early stage and there is no certainty that they will lead to a transaction,” Biotest said in a statement.
Biotest added that China-based Creat had informed its board that no sale process has been initiated to date nor any decision made about a future sale.
